Spectral AI Inc (MDAI)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$1.57+0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · MDAI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -32.7% |
| Our one-year growth estimate | diamond | 77.7% |
Growth built into the price is above our model estimate.
The price assumes 110.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
MDAI — officer change
Dated 2026-02-03
Chief Commercial Officer — Mr. Jeremiah Sparks: Mr. Jeremiah Sparks is leaving the company to pursue other opportunities.
Why it matters: Sales in other countries could greatly increase revenue. It would also show the product's global appeal.
Supportive ifThe company plans to announce first sales of the DeepView System in the UK, Australia, or GCC by Q4 2026.
Worry ifNo updates or sales in other countries by the end of 2026. This may show regulatory or market entry problems.
Why it matters: Earnings results will show if the company is on track to meet its $18.5 million revenue target for 2026.
Watch forRevenue for Q2 2026 is over $5 million. This shows progress toward the $18.5 million goal.
Also watch forRevenue for Q2 2026 is under $4 million. This suggests problems in reaching the yearly target.
Why it matters: New leadership can impact company direction and strategy. Their effectiveness is key for growth.
Watch forGood results or important news from the new CEO or CFO.
Also watch forBad news or slow progress in company plans with new leaders.
Why it matters: If sector revenue growth picks up, it could benefit MDAI as it operates in a maturing sector.
Supportive ifSector revenue growth is speeding up to 10% or more.
Worry ifSector revenue growth keeps slowing down to below 5%.
Why it matters: Starting this study is important. It will show how well the DeepView System works in clinics.
Supportive ifThe company officially announces the start of the Outcome Study in Q4 2026.
Worry ifThe study is delayed or has not started as planned. This raises worries about the product's testing.
Why it matters: The study will show how well the DeepView System works. This affects sales.
Watch forThe study shows the DeepView System helps with surgery and treatment choices.
Also watch forThe study does not show clear benefits from using the DeepView System.
Why it matters: First sales will mark a major shift from development to commercial operations. This is crucial for revenue growth.
Supportive ifThe company announces the first commercial sales of the DeepView System in the U.S.
Worry ifNo sales reported by the end of 2026.
Why it matters: This study will show how well the DeepView System helps patient care.
Watch forThe company starts the Triage and Treatment Outcome Study in Q4 2026.
Also watch forThe study is delayed or not initiated as planned in Q4 2026.
Why it matters: This guidance shows revenue expectations are steady, even with recent drops.
Watch forThe company confirms revenue guidance of about $18.5 million for 2026.
Also watch forThe company revises revenue guidance down from $18.5 million for 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $719 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,455 loss on $10,000 · 54.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.